EarningsQ2 2026 Earnings Report
CH:DUL Q2 2026 EPS Results
Actual EPSCHF1.01
Consensus EPSCHF1.35
Beat/MissMissed by -CHF0.35
One Year Ago EPS-CHF0.42
CH:DUL Q2 2026 Revenue Results
Actual RevenueCHF1.07B
Expected RevenueCHF1.10B
Beat/MissMissed by -CHF25.92M
YoY Revenue Growth+66.86%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
CH:DUL Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CH:DUL Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum — highlighted by record quarterly AMVUTTRA and broad TTR revenue growth, expanding prescriber base, robust cash and operating income, strategic geographic and AI partnerships, and an active pipeline with upcoming data readouts. Negative elements included a $200M downward revision to 2026 TTR guidance tied to normalization of early switch demand, a Q2 decline in collaboration revenue, margin pressure from higher royalties, increased R&D/SG&A investment, and industry uncertainty following a competitor trial failure (CARDIO-TTRansform). Management framed the guidance reduction as a learning from early launch dynamics and emphasized confidence in long-term TTR leadership and nucresiran’s prospects, indicating highlights outweigh challenges.Company Guidance
AMVUTTRA Milestone Quarterly Revenue
AMVUTTRA revenue exceeded $1.0 billion in Q2 2026 — the first time a single quarter surpassed $1B — implying an annual run rate above $4.0 billion just 15 months after the ATTR-CM launch.
Strong Overall Product Revenue Growth
Total global net product revenues were approximately $1.2 billion in Q2 2026, up 74% year-over-year, reflecting robust uptake of AMVUTTRA and ATTR-CM.
TTR Franchise Expansion
Global TTR net revenues reached $1.03 billion in Q2 (13% sequential growth vs Q1 and 89% YoY). U.S. TTR revenues rose 15% vs Q1 and 114% YoY; ex-U.S. TTR revenues increased 7% vs Q1 and 31% YoY. First-line new patient starts accounted for ~80% of category growth.
Royalty and Collaboration Upside
Royalty revenue increased 79% to $72 million in Q2 driven by higher LEQVIO sales; collaboration & royalty full-year guidance raised to $575M–$625M (a $150M midpoint increase) reflecting stronger partner performance and reimbursable development activity.
Profitability and Cash Position
Non-GAAP operating income was $318 million (more than triple year-ago level). Cash, cash equivalents and marketable securities were $3.3 billion at quarter end, up from $2.9 billion at year-end 2025.
Commercial Execution and Prescriber Expansion
Since the ATTR-CM launch, the company added over 1,700 new prescribers; among prescribers using AMVUTTRA it represents >50% of new patient starts, and adherence remains >90% in the real-world data cited.
Geographic and Strategic Expansion
Announced collaboration with BeOne for exclusive commercialization and distribution rights for AMVUTTRA in Mainland China and Macau (subject to approval), and broadened AI partnerships (Inceptive, Viz AI, Komodo Health, a large California health system) to accelerate discovery, diagnosis and commercial execution.
Pipeline Progress and Clinical Milestones
Progressed multiple programs: initiated Phase II trials (ALN-6400 in von Willebrand disease; mivelsiran in Down syndrome–associated Alzheimer's), expanded TRITON-CM enrollment to ~1,750 patients, progress on 3 ongoing Phase III programs, and anticipated several H2 2026 data readouts (including Phase I ALN-HTT02 results in October). Guidance includes continued IND filings (3–4 per year).
CH:DUL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed